Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — Corporate Update (January 2026)
20 slides from Jasper Therapeutics's corporate update, Jan 8, 2026
Slide 1: BEACON & OLE Data Update
Jasper Therapeutics BEACON & OLE Data Update January 8, 2026 Exhibit 99.2
Slide 2: Safe Harbor Statements
2 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statements. All statements other than statemen
Slide 3: New BEACON and OLE data support advancing into a Phase 2b CSU study in 2H 2026
3 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION New BEACON and OLE data support advancing into a Phase 2b CSU study in 2H 2026 Briquilimab’s unique drug properties allow for rapid clinical efficacy while minimizing KIT related AEs • Briquilimab’s MOA (direct ligand/rece
Slide 4: BEACON & OLE Data Update
BEACON & OLE Data Update Dr. Daniel Adelman, Acting CMO Jasper Therapeutics Open - Label Extension Study +
Slide 5: January 2026 BEACON Study & OLE Study Data Update
5 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION January 2026 BEACON Study & OLE Study Data Update Briquilimab continues to demonstrate rapid and durable clinical responses • BEACON Cohort 9.1 patients reaffirms strong efficacy and safety profile • Mean reduction in UAS7
Slide 6: Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria
6 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION • UAS7 ≥ 16 • 18+ years Screening/Eligibility • CSU diagnosis ≥ 6 mos. • H1 - antihistamine - failed Study Operations • US Lead: Tom Casale, MD • EU Lead: Martin Metz, MD • ~30 sites in the US & EU Key Assessments • Diseas
Slide 7: Rapid and deep reductions in tryptase with initial 240mg or higher dose
7 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Rapid and deep reductions in tryptase with initial 240mg or higher dose Data cut - off 2 Jan 2026 Serum Tryptase (ng/ml) 12 10 8 6 4 2 360mg (SD) (n=5) 0 0 1 Placebo (n=21) 240mg Q8W (n=6) 2 4 Week 240mg (SD) (n=6) 240mg -
Slide 8: New 240mg/180mg Q8W data demonstrate rapid and sustained UAS7 response
8 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION New 240mg/180mg Q8W data demonstrate rapid and sustained UAS7 response 31 - point reduction in mean UAS7 score at week 12 with new 9.1 cohort Mean UAS7 0 35 30 25 20 15 10 5 40 0 1 2 3 4 5 6 7 Week 8 9 Placebo (n=21) Cohor
Slide 9: New 240mg/180mg Q8W patients demonstrate rapid and durable responses
9 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Response (%) 90 80 70 60 50 40 30 20 10 0 100 1 2 3 4 5 6 7 Week 8 9 10 11 12 CR + WC CR New 240mg/180mg Q8W patients demonstrate rapid and durable responses 83% of patients with complete response at week 3 (n=6) Data cut
Slide 10: Briquilimab well tolerated with favorable safety profile demonstrated
10 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab well tolerated with favorable safety profile demonstrated Total Pooled Placebo (N= 21 ) 12 ( 57 . 1 ) Total Pooled Briquilimab (N=64) 4 48 (75) Cohort 9.1 240mg 180mg Q8W (N=6) 6 (100) Cohort 9 240mg 180mg Q8W
Slide 11: Safety/tolerability observations possibly related to KIT blockade were generally limited to low grade events
11 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safety/tolerability observations possibly related to KIT blockade were generally limited to low grade events Majority resolved during repeat dosing and none resulted in discontinuations or dose delays Pooled Placebo (N= 2
Slide 12: Jasper Chronic Urticaria Open Label Extension Study (JSP-CP-014)
12 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Screening/Eligibility • To enroll, patients from BEACON/SPOTLIGHT must either: • Wait for symptoms to return following dosing (defined as UAS7 ≥ 16 for CSU, UCT ≤ 12 for CIndU) • OR complete the BEACON/SPOTLIGHT study Key
Slide 13: CIndU OLE: Clinical responses maintained at 24 weeks with 180mg Q8W
13 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION CIndU OLE: Clinical responses maintained at 24 weeks with 180mg Q8W • 17 CIndU patients rolled over from SPOTLIGHT • Continued to observe a rapid onset of effect: o 11 of 16 patients (69%) achieved either CR or PR by week
Slide 14: CSU OLE: Continues to show increasing efficacy over time at 180mg Q8W
14 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION 0 5 10 15 20 25 30 35 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 n=46 CSU OLE: Continues to show increasing efficacy over time at 180mg Q8W 22.4 pt reduction in UAS7 at week 12 and 62% Complete Response rate obs
Slide 15: Briquilimab well tolerated with favorable safety profile in the OLE study
15 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab 180mg Q8W (n=63) Briquilimab well tolerated with favorable safety profile in the OLE study Low rate of safety/tolerability observations possibly related to KIT blockade in OLE Briquilimab 180mg Q8W (n=63) 1 (1
Slide 16: Conclusion and Next Steps
Conclusion and Next Steps Jeet Mahal, CEO
Slide 17: Briquilimab complete response and well controlled disease at 12 weeks
17 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab complete response and well controlled disease at 12 weeks Note: These observations are derived from separate clinical settings; comparisons across trials are not based on head - to - head studies. 51% 38% Briq
Slide 18: Briquilimab demonstrated rapid and deep onset of disease control
18 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab demonstrated rapid and deep onset of disease control 45 Briquilimab (BEACON) Barzolvolimab (Phase II) 1 Placebo, n=21 Placebo, n=51 40 180mg Q8W (OLE), n=36 150mg Q4W, n=52 240mg single dose, n=5 300mg Q8W, n=
Slide 19: January 2026 Chronic Urticaria Data Update
19 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION January 2026 Chronic Urticaria Data Update Briquilimab demonstrates rapid efficacy and a favorable chronic safety profile • Rapid and durable clinical responses • Repeat dose safety data now available for more than 50 pat
Slide 20: Jasper Therapeutics January 2026
Jasper Therapeutics NASDAQ: JSPR January 2026
Jasper Therapeutics — Corporate Update (January 2026) on 6ix